{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:14:14Z","timestamp":1768418054766,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00117-025-01549-4","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:13:06Z","timestamp":1765973586000},"page":"47-58","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nebenwirkungen von Immuntherapien","Abdominal immune-related adverse events"],"prefix":"10.1007","volume":"66","author":[{"given":"Fabian","family":"Bauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Persigehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"1549_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih\u00a0H, Tang\u00a0T, Lu\u00a0Y et\u00a0al (2019) Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. j immunotherapy cancer 7:31","journal-title":"j immunotherapy cancer"},{"key":"1549_CR2","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00261-019-01935-2","volume":"44","author":"F Alessandrino","year":"2019","unstructured":"Alessandrino\u00a0F, Sahu\u00a0S, Nishino\u00a0M et\u00a0al (2019) Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD\u20111 inhibitor. Abdom Radiol 44:1917\u20131927","journal-title":"Abdom Radiol"},{"key":"1549_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.crad.2017.04.003","volume":"72","author":"F Alessandrino","year":"2017","unstructured":"Alessandrino\u00a0F, Tirumani\u00a0SH, Krajewski\u00a0KM et\u00a0al (2017) Imaging of hepatic toxicity of systemic therapy in a\u00a0tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol 72:521\u2013533","journal-title":"Clin Radiol"},{"key":"1549_CR4","doi-asserted-by":"crossref","unstructured":"Anderson MA, Kurra V, Bradley W et\u00a0al (2020) Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. Br J Radiol 94:","DOI":"10.1259\/bjr.20200663"},{"key":"1549_CR5","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia\u00a0P, Phan\u00a0GQ, Maker\u00a0AV et\u00a0al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T\u2011lymphocyte antigen\u20114. J\u00a0Clin Oncol 23:6043\u20136053","journal-title":"J Clin Oncol"},{"key":"1549_CR6","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","volume":"40","author":"S Bacanovic","year":"2015","unstructured":"Bacanovic\u00a0S, Burger\u00a0IA, Stolzmann\u00a0P et\u00a0al (2015) Ipilimumab-Induced Adrenalitis: A\u00a0Possible Pitfall in 18F-FDG-PET\/CT. Clin Nucl Med 40:e518\u2013519","journal-title":"Clin Nucl Med"},{"key":"1549_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s15004-024-0821-9","volume":"27","author":"P Br\u00f6ckelmann","year":"2024","unstructured":"Br\u00f6ckelmann\u00a0P, Hassel\u00a0J (2024) Nebenwirkungsmanagement bei Immuncheckpointinhibition. InFo H\u00e4matol Onkol 27:10\u201315","journal-title":"InFo H\u00e4matol Onkol"},{"key":"1549_CR8","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno\u00a0JN, Maus\u00a0MV, Hinrichs\u00a0CS (2024) CAR T Cells and T\u2011Cell Therapies for Cancer: A\u00a0Translational Science Review. JAMA 332:1924\u20131935","journal-title":"JAMA"},{"key":"1549_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun\u00a0DJ, Wolchok\u00a0JD, Rosenberg\u00a0LM et\u00a0al (2017) Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13:195\u2013207","journal-title":"Nat Rev Endocrinol"},{"key":"1549_CR10","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s00261-022-03555-9","volume":"47","author":"L Calistri","year":"2022","unstructured":"Calistri\u00a0L, Maraghelli\u00a0D, Nardi\u00a0C et\u00a0al (2022) Magnetic resonance imaging of inflammatory pseudotumor of the liver: a\u00a02021 systematic literature update and series presentation. Abdom Radiol 47:2795\u20132810","journal-title":"Abdom Radiol"},{"key":"1549_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1148\/radiol.2018180572","volume":"289","author":"SC Cheshire","year":"2018","unstructured":"Cheshire\u00a0SC, Board\u00a0RE, Lewis\u00a0AR et\u00a0al (2018) Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma. Radiology 289:564\u2013567","journal-title":"Radiology"},{"key":"1549_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41379-020-00653-1","volume":"34","author":"JV Cohen","year":"2021","unstructured":"Cohen\u00a0JV, Dougan\u00a0M, Zubiri\u00a0L et\u00a0al (2021) Liver biopsy findings in patients on immune checkpoint inhibitors. Mod Pathol 34:426\u2013437","journal-title":"Mod Pathol"},{"key":"1549_CR13","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.cgh.2020.01.033","volume":"18","author":"M Collins","year":"2020","unstructured":"Collins\u00a0M, Soularue\u00a0E, Marthey\u00a0L et\u00a0al (2020) Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A\u00a0Systematic Review. Clin Gastroenterol Hepatol 18:1393\u20131403.e1391","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1549_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar\u00a0FB, Kibbelaar\u00a0ZA, Glezerman\u00a0IG et\u00a0al (2020) Clinical Features and Outcomes of Immune Checkpoint Inhibitor\u2013Associated AKI: A\u00a0Multicenter Study. J\u00a0Am Soc Nephrol 31:435\u2013446","journal-title":"J Am Soc Nephrol"},{"key":"1549_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J De Filette","year":"2019","unstructured":"De Filette\u00a0J, Andreescu\u00a0CE, Cools\u00a0F et\u00a0al (2019) A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res 51:145\u2013156","journal-title":"Horm Metab Res"},{"key":"1549_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1148\/rg.210065","volume":"42","author":"PM De Groot","year":"2022","unstructured":"De Groot\u00a0PM, Arevalo\u00a0O, Shah\u00a0K et\u00a0al (2022) Imaging Primer on Chimeric Antigen Receptor T\u2011Cell Therapy for Radiologists. Radiographics 42:176\u2013194","journal-title":"Radiographics"},{"key":"1549_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille\u00a0C, Ederhy\u00a0S, Sassier\u00a0M et\u00a0al (2020) Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol 6:865\u2013871","journal-title":"JAMA Oncol"},{"key":"1549_CR18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","volume":"184","author":"M Dougan","year":"2021","unstructured":"Dougan\u00a0M, Luoma\u00a0AM, Dougan\u00a0SK et\u00a0al (2021) Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 184:1575\u20131588","journal-title":"Cell"},{"key":"1549_CR19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","volume":"159","author":"Y Du","year":"2023","unstructured":"Du\u00a0Y, Wu\u00a0W, Chen\u00a0M et\u00a0al (2023) Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A\u00a0Systematic Review and Meta-Analysis. JAMA Dermatol 159:1093\u20131101","journal-title":"JAMA Dermatol"},{"key":"1549_CR20","doi-asserted-by":"publisher","first-page":"e252668","DOI":"10.1001\/jamanetworkopen.2025.2668","volume":"8","author":"SM Durbin","year":"2025","unstructured":"Durbin\u00a0SM, Zubiri\u00a0L, Perlman\u00a0K et\u00a0al (2025) Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. JAMA Network Open 8:e252668\u2013e252668","journal-title":"JAMA Network Open"},{"key":"1549_CR21","first-page":"4607","volume":"32","author":"PM Forde","year":"2012","unstructured":"Forde\u00a0PM, Rock\u00a0K, Wilson\u00a0G et\u00a0al (2012) Ipilimumab-induced Immune-related Renal Failure\u2014A Case Report. Anticancer Res 32:4607","journal-title":"Anticancer Res"},{"key":"1549_CR22","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/ckj\/sfac109","volume":"15","author":"AO G\u00e9rard","year":"2022","unstructured":"G\u00e9rard\u00a0AO, Barbosa\u00a0S, Parassol\u00a0N et\u00a0al (2022) Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a\u00a0case-control study. Clin Kidney\u00a0J 15:1881\u20131887","journal-title":"Clin Kidney J"},{"key":"1549_CR23","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis\u00a0P, Jochum\u00a0F, Abbar\u00a0B et\u00a0al (2024) Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a\u00a0decade\u2014a worldwide perspective. EClinicalMedicine 70:102536","journal-title":"EClinicalMedicine"},{"key":"1549_CR24","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen\u00a0J, Obeid\u00a0M, Spain\u00a0L et\u00a0al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1217\u20131238","journal-title":"Ann Oncol"},{"key":"1549_CR25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann\u00a0L, Forschner\u00a0A, Loquai\u00a0C et\u00a0al (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1\u00a0therapy. Eur J Cancer 60:190\u2013209","journal-title":"Eur J Cancer"},{"key":"1549_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","volume":"67","author":"J Kashima","year":"2018","unstructured":"Kashima\u00a0J, Okuma\u00a0Y, Shimizuguchi\u00a0R et\u00a0al (2018) Bile duct obstruction in a\u00a0patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a\u00a0case report. Cancer Immunol Immunother 67:61\u201365","journal-title":"Cancer Immunol Immunother"},{"key":"1549_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami\u00a0H, Tanizaki\u00a0J, Tanaka\u00a0K et\u00a0al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529\u2013536","journal-title":"Invest New Drugs"},{"key":"1549_CR28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","volume":"31","author":"KW Kim","year":"2013","unstructured":"Kim\u00a0KW, Ramaiya\u00a0NH, Krajewski\u00a0KM et\u00a0al (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31:1071\u20131077","journal-title":"Invest New Drugs"},{"key":"1549_CR29","doi-asserted-by":"publisher","first-page":"W468","DOI":"10.2214\/AJR.12.9751","volume":"200","author":"KW Kim","year":"2013","unstructured":"Kim\u00a0KW, Ramaiya\u00a0NH, Krajewski\u00a0KM et\u00a0al (2013) Ipilimumab-Associated Colitis: CT Findings. Am J Roentgenol 200:W468\u2013W474","journal-title":"Am J Roentgenol"},{"key":"1549_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin\u00a0J, Chiarion-Sileni\u00a0V, Gonzalez\u00a0R et\u00a0al (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N\u00a0Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"key":"1549_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ndt\/gfy105","volume":"34","author":"S Manohar","year":"2019","unstructured":"Manohar\u00a0S, Kompotiatis\u00a0P, Thongprayoon\u00a0C et\u00a0al (2019) Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant 34:108\u2013117","journal-title":"Nephrol Dial Transplant"},{"key":"1549_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins\u00a0F, Sofiya\u00a0L, Sykiotis\u00a0GP et\u00a0al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580","journal-title":"Nat Rev Clin Oncol"},{"key":"1549_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","volume":"96","author":"A Mekki","year":"2018","unstructured":"Mekki\u00a0A, Dercle\u00a0L, Lichtenstein\u00a0P et\u00a0al (2018) Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96:91\u2013104","journal-title":"Eur J Cancer"},{"key":"1549_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40644-023-00580-9","volume":"23","author":"S M\u00f6nch","year":"2023","unstructured":"M\u00f6nch\u00a0S, Heimer\u00a0MM, Winkelmann\u00a0M et\u00a0al (2023) Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors. Cancer Imaging 23:58","journal-title":"Cancer Imaging"},{"key":"1549_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1148\/radiol.2018181349","volume":"290","author":"M Nishino","year":"2019","unstructured":"Nishino\u00a0M, Hatabu\u00a0H, Hodi\u00a0FS (2019) Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. Radiology 290:9\u201322","journal-title":"Radiology"},{"key":"1549_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1148\/radiol.2020200443","volume":"297","author":"HJ Park","year":"2020","unstructured":"Park\u00a0HJ, Kim\u00a0KW, Pyo\u00a0J et\u00a0al (2020) Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A\u00a0Systematic Review and Meta-Analysis. Radiology 297:87\u201396","journal-title":"Radiology"},{"key":"1549_CR37","doi-asserted-by":"publisher","first-page":"e001198","DOI":"10.1136\/jitc-2020-001198","volume":"8","author":"V Patel","year":"2020","unstructured":"Patel\u00a0V, Elias\u00a0R, Formella\u00a0J et\u00a0al (2020) Acute interstitial nephritis, a\u00a0potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. j immunotherapy cancer 8:e1198","journal-title":"j immunotherapy cancer"},{"key":"1549_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","volume":"24","author":"S Paul","year":"2024","unstructured":"Paul\u00a0S, Konig\u00a0MF, Pardoll\u00a0DM et\u00a0al (2024) Cancer therapy with antibodies. Nat Rev Cancer 24:399\u2013426","journal-title":"Nat Rev Cancer"},{"key":"1549_CR39","doi-asserted-by":"publisher","first-page":"175883591983082","DOI":"10.1177\/1758835919830826","volume":"11","author":"MS Pelster","year":"2019","unstructured":"Pelster\u00a0MS, Amaria\u00a0RN (2019) Combined targeted therapy and immunotherapy in melanoma: a\u00a0review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther Adv Med Oncol 11:1758835919830826","journal-title":"Ther Adv Med Oncol"},{"key":"1549_CR40","doi-asserted-by":"crossref","unstructured":"Pi B, Wang J, Tong Y et\u00a0al (2021) Immune-related cholangitis induced by immune checkpoint inhibitors: a\u00a0systematic review of clinical features and management. Eur J Gastroenterol Hepatol 33:","DOI":"10.1097\/MEG.0000000000002280"},{"key":"1549_CR41","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","volume":"15","author":"E Raschi","year":"2020","unstructured":"Raschi\u00a0E, Gatti\u00a0M, Gelsomino\u00a0F et\u00a0al (2020) Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A\u00a0Clinical Perspective from Pharmacovigilance. Targ Oncol 15:449\u2013466","journal-title":"Targ Oncol"},{"key":"1549_CR42","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","volume":"23","author":"K Reynolds","year":"2018","unstructured":"Reynolds\u00a0K, Thomas\u00a0M, Dougan\u00a0M (2018) Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. The Oncol 23:991\u2013997","journal-title":"The Oncol"},{"key":"1549_CR43","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert\u00a0C, Schachter\u00a0J, Long\u00a0GV et\u00a0al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N\u00a0Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"key":"1549_CR44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder\u00a0M, Callahan\u00a0M, Postow\u00a0MA et\u00a0al (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a\u00a0comprehensive retrospective review from a\u00a0single institution. Endocr Relat Cancer 21:371\u2013381","journal-title":"Endocr Relat Cancer"},{"key":"1549_CR45","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso\u00a0BD, Nastoupil\u00a0LJ, Adkins\u00a0S et\u00a0al (2021) Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T\u2011Cell Therapy: ASCO Guideline. JCO 39:3978\u20133992","journal-title":"JCO"},{"key":"1549_CR46","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider\u00a0BJ, Naidoo\u00a0J, Santomasso\u00a0BD et\u00a0al (2021) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. JCO 39:4073\u20134126","journal-title":"JCO"},{"key":"1549_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert\u00a0ML, Schmitt\u00a0M, Wang\u00a0L et\u00a0al (2021) Side-effect management of chimeric antigen receptor (CAR) T\u2011cell therapy. Ann Oncol 32:34\u201348","journal-title":"Ann Oncol"},{"key":"1549_CR48","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma\u00a0P, Goswami\u00a0S, Raychaudhuri\u00a0D et\u00a0al (2023) Immune checkpoint therapy\u2014current perspectives and future directions. Cell 186:1652\u20131669","journal-title":"Cell"},{"key":"1549_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen\u00a0A, G\u00f6del\u00a0P, Subklewe\u00a0M et\u00a0al (2018) Cytokine release syndrome. J\u00a0Immunother Cancer 6:56","journal-title":"J Immunother Cancer"},{"key":"1549_CR50","doi-asserted-by":"publisher","first-page":"e513","DOI":"10.1097\/RLU.0000000000004224","volume":"47","author":"TTH Goyal","year":"2022","unstructured":"Goyal\u00a0TTH, Singh\u00a0H et\u00a0al (2022) Nivolumab Immunotherapy\u2013Related Skin Reactions Detected on 18F-FDG PET\/CT in Renal Cell Cancer. Clin Nucl Med 47:e513\u2013e514","journal-title":"Clin Nucl Med"},{"key":"1549_CR51","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2020.790","volume":"53","author":"S-Q Tang","year":"2021","unstructured":"Tang\u00a0S\u2011Q, Tang\u00a0L\u2011L, Mao\u00a0Y\u2011P et\u00a0al (2021) The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A\u00a0Pooled Analysis of 23 Clinical Trials and 8,436 Patients. Cancer Res Treat 53:339\u2013354","journal-title":"Cancer Res Treat"},{"key":"1549_CR52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.acra.2016.08.005","volume":"24","author":"JW Wachsmann","year":"2017","unstructured":"Wachsmann\u00a0JW, Ganti\u00a0R, Peng\u00a0F (2017) Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT. Acad Radiol 24:111\u2013115","journal-title":"Acad Radiol"},{"key":"1549_CR53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo\u00a0R, Karam\u00a0S, Uppal\u00a0NN et\u00a0al (2017) Adverse Renal Effects of Immune Checkpoint Inhibitors: A\u00a0Narrative Review. Am J Nephrol 45:160\u2013169","journal-title":"Am J Nephrol"},{"key":"1549_CR54","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1148\/rg.2017170085","volume":"37","author":"GX Wang","year":"2017","unstructured":"Wang\u00a0GX, Kurra\u00a0V, Gainor\u00a0JF et\u00a0al (2017) Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. Radiographics 37:2132\u20132144","journal-title":"Radiographics"},{"key":"1549_CR55","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang\u00a0J, Hu\u00a0Y, Yang\u00a0S et\u00a0al (2019) Role of Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T\u00a0Cell Therapy in Patients with Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant 25:1092\u20131098","journal-title":"Biol Blood Marrow Transplant"},{"key":"1549_CR56","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber\u00a0JS, K\u00e4hler\u00a0KC, Hauschild\u00a0A (2012) Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. JCO 30:2691\u20132697","journal-title":"JCO"},{"key":"1549_CR57","first-page":"1355","volume":"32","author":"S Wilgenhof","year":"2012","unstructured":"Wilgenhof\u00a0S, Morlion\u00a0V, Seghers\u00a0AC et\u00a0al (2012) Sarcoidosis in a\u00a0Patient with Metastatic Melanoma Sequentially Treated with Anti-CTLA\u20114 Monoclonal Antibody and Selective BRAF Inhibitor. Anticancer Res 32:1355","journal-title":"Anticancer Res"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-025-01549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-025-01549-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-025-01549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:02:54Z","timestamp":1768388574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-025-01549-4"}},"subtitle":["Fokus Abdomen","Abdominal focus"],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1007\/s00117-025-01549-4","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Bauer und T.\u00a0Persigehl geben an, dass kein Interessenskonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}